BLAINJECTIONINJECTABLE
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BYOOVIZ (ranibizumab-nuna) by Samsung Bioepis is vascular endothelial growth factor inhibitors [moa]. First approved in 2021.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYOOVIZ (ranibizumab-nuna) is a monoclonal antibody biosimilar that inhibits vascular endothelial growth factor (VEGF) to treat retinal and ocular diseases. It is a Samsung Bioepis biosimilar referencing the originator ranibizumab product. The drug is administered via intravitreal injection to prevent abnormal blood vessel growth and vision loss in conditions such as age-related macular degeneration and diabetic retinopathy.
Peak
Product is in peak lifecycle with established market presence; commercial teams should focus on market share defense and pricing strategy in a moderately competitive biosimilar landscape.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BYOOVIZ offers career opportunities in a mature biosimilar market segment with emphasis on commercial execution, payer relationships, and formulary placement. Professionals joining this product will focus on defending market share and optimizing pricing in a competitive ophthalmology landscape rather than early-stage development activities.
Brand Manager
Worked on BYOOVIZ at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.